Incyte Corp. (INCY): Price and Financial Metrics

Incyte Corp. (INCY): $78.26

0.50 (+0.64%)

POWR Rating

Component Grades













Add INCY to Watchlist
Sign Up

Industry: Biotech



in industry


  • INCY scores best on the Quality dimension, with a Quality rank ahead of 96.44% of US stocks.
  • The strongest trend for INCY is in Quality, which has been heading up over the past 179 days.
  • INCY's current lowest rank is in the Growth metric (where it is better than 5.26% of US stocks).

INCY Stock Summary

  • INCYTE CORP's market capitalization of $17,046,070,358 is ahead of 88.53% of US-listed equities.
  • For INCY, its debt to operating expenses ratio is greater than that reported by just 5.72% of US equities we're observing.
  • In terms of volatility of its share price, INCY is more volatile than merely 7.7% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INCYTE CORP are EXEL, QRVO, SMCI, GLYC, and NBTX.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to

INCY Valuation Summary

  • In comparison to the median Healthcare stock, INCY's price/sales ratio is 168.42% higher, now standing at 5.1.
  • INCY's price/earnings ratio has moved up 21.6 over the prior 243 months.

Below are key valuation metrics over time for INCY.

Stock Date P/S P/B P/E EV/EBIT
INCY 2022-11-01 5.1 4.1 19.5 25.3
INCY 2022-10-31 5.0 4.0 17.5 22.4
INCY 2022-10-28 5.0 4.1 17.6 22.5
INCY 2022-10-27 4.9 4.0 17.1 21.8
INCY 2022-10-26 4.9 4.0 17.3 22.1
INCY 2022-10-25 4.9 3.9 17.0 21.7

INCY Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -142.14%.
  • Its 4 year net cashflow from operations growth rate is now at -142.14%.
  • The 4 year price growth rate now stands at -19.87%.
INCY's revenue has moved up $610,209,000 over the prior 15 months.

The table below shows INCY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3,330.788 801.63 876.05
2022-06-30 3,320.472 760.347 945.014
2022-03-31 3,114.784 759.134 933.038
2021-12-31 2,986.267 749.488 948.581
2021-09-30 2,912.923 741.458 534.58
2021-06-30 2,720.579 668.475 337.638

INCY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INCY has a Quality Grade of A, ranking ahead of 95.94% of graded US stocks.
  • INCY's asset turnover comes in at 0.76 -- ranking 198th of 563 Business Services stocks.
  • TSSI, APDN, and NUAN are the stocks whose asset turnover ratios are most correlated with INCY.

The table below shows INCY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.760 0.951 0.546
2021-06-30 0.754 0.949 0.381
2021-03-31 0.787 0.951 0.523
2020-12-31 0.831 0.951 -0.231
2020-09-30 0.774 0.948 -0.298
2020-06-30 0.758 0.949 -0.138

INCY Price Target

For more insight on analysts targets of INCY, see our INCY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $102.47 Average Broker Recommendation 1.56 (Moderate Buy)

INCY Stock Price Chart Interactive Chart >

Price chart for INCY

INCY Price/Volume Stats

Current price $78.26 52-week high $84.86
Prev. close $77.76 52-week low $63.40
Day low $77.27 Volume 238,700
Day high $78.26 Avg. volume 1,512,534
50-day MA $72.18 Dividend yield N/A
200-day MA $74.16 Market Cap 17.41B

Incyte Corp. (INCY) Company Bio

ncyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. (Source:Wikipedia)

INCY Latest News Stream

Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream

Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del., November 17, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November and December:

Yahoo | November 17, 2022

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab.

GlobeNewswire | November 10, 2022

Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SITC22--Data from Incyte’s Oncology Portfolio to be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Business Wire | November 7, 2022

Incyte, Mirati team up for trial of combo therapy for solid tumors

Incyte (INCY) and Mirati Therapeutics (MRTX) entered a clinical trial collaboration and supply agreement.The companies will evaluate a combination of Incyte''s small molecule…

Seeking Alpha | November 7, 2022

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

WILMINGTON, Del. & SAN DIEGO, Calif., November 07, 2022--Incyte and Mirati Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in KRASG12C-Mutated Solid Tumors

Yahoo | November 7, 2022

Read More 'INCY' Stories Here

INCY Price Returns

1-mo 7.41%
3-mo 9.49%
6-mo N/A
1-year 14.45%
3-year -16.85%
5-year -20.03%
YTD 6.62%
2021 -15.61%
2020 -0.39%
2019 37.32%
2018 -32.86%
2017 -5.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5797 seconds.